Recombinant Human VEGFR2/KDR/Flk-1 Fc Avi-tag Protein, CF

R&D Systems, part of Bio-Techne | Catalog # AVI10460

Biotinylated
R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
AVI10460-050
100% Guarantee

Key Product Details

Learn more about Avi-tag Biotinylated Proteins

Source

HEK293

Accession #

AAC16450.1

Structure / Form

Disulfide-linked homodimer, biotinylated via Avi-tag

Conjugate

Biotin

Applications

Bioactivity

View all VEGFR2/KDR/Flk-1 Proteins and Enzymes »

Product Specifications

Source

Human embryonic kidney cell, HEK293-derived human VEGFR2/KDR/Flk-1 protein
Human VEGFR2/KDR/Flk-1
(Ala20-Glu764)
Accession # AAC16450.1		 IEGRMD Human IgG1
(Pro100-Lys330)		 Avi-tag
N-terminus C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Ala20

Predicted Molecular Mass

111 kDa

SDS-PAGE

145-165 kDa, under reducing conditions

Activity

Measured by its binding ability in a functional ELISA.
When Recombinant Human VEGF165  (Catalog # 293-VE) is immobilized at 1 µg/mL (100 µL/well), Biotinylated Recombinant Human VEGFR2/KDR/Flk-1 Fc Chimera Avi-tag (Catalog # AVI10460) binds with an ED50 of 4-40 ng/mL.

Scientific Data Images for Recombinant Human VEGFR2/KDR/Flk-1 Fc Avi-tag Protein, CF

Recombinant Human VEGFR2/KDR/Flk-1 Fc Avi-tag Protein Binding Activity

Recombinant Human VEGFR2/KDR/Flk-1 Fc Avi-tag Protein Binding Activity

When Recombinant Human VEGF 165 (293-VE) is immobilized at 1 μg/mL (100 μL/well), Biotinylated Recombinant Human VEGFR2/KDR/Flk-1 Fc Chimera Avi-tag (AVI10460) binds with an ED50 of 4-40 ng/mL.
Recombinant Human VEGFR2/KDR/Flk-1 Fc Avi-tag Protein SDS-PAGE

Recombinant Human VEGFR2/KDR/Flk-1 Fc Avi-tag Protein SDS-PAGE

2 μg/lane of Biotinylated Recombinant Human VEGFR2/KDR/Flk-1 Fc Chimera Avi-tag (AVI10460) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 145-165 kDa and 290-330 kDa, respectively.

Formulation, Preparation and Storage

AVI10460
Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution Reconstitute at 500 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: VEGFR2/KDR/Flk-1

Vascular endothelial Growth Factor Receptor 2 (VEGFR2), also known as FLK-1, KDR, and CD309, is a type I single-pass membrane receptor. Mature VEGFR2 contains a 745 amino acid extracelluar domain with seven immunoglobulin-like repeats, 21 transmembrane domain and 571 cytoplasmic domain. Within the extracellular domain, human VEGFR2 shares 80% homology with that of mouse and rat. VEGFR2, VEGFR1(Flt-1) and VEGFR3(Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors have almost exclusive expression in the endothelial cells and play essential roles in vasculogenesis and angiogenesis. VEGFR2 is the receptor for VEGF-A, VEGF-C, VEGF-D, and VEGF-E (viral homologs) (1, 2). Monomeric VEGFR2 dimerizes after binding to dimeric ligand and phosphorylate the Tyr in the cytoplasmic domain (3). VEGFR2 can also form heterodimer with VEGFR1 and VEGFR3 (4-6). Alternative splicing isoforms 2 and 3 which lack the transmembrane and cytoplasmic domains function as decoy receptors (7, 8). Targeting the signaling pathways of VEGFR1 and VEGFR2 are potential therapeutic targets for the treatment of inflammation and multiple tumors including breast, gastric, and lung carcinomas (9-12). Cancer immunotherapies using VEGF and VEGFR2 monoclonal antibodies may also be effective in combination with programmed cell death protein 1 (PD-1)/ programmed cell death ligand 1 (PD-L1) immune checkpoint blockade (13). Our Avi-tag Biotinylated VEGFR2 features biotinylation at a single site contained within the Avi-tag, a unique 15 amino acid peptide. Protein orientation will be uniform when bound to streptavidin-coated surface due to the precise control of biotinylation and the rest of the protein is unchanged so there is no interference in the protein's bioactivity.

References

  1. Ferra, N. and Davis-Smyth, T. (1997) Endocr. Rev. 18:4.
  2. Wise, L.M. et al. (2012) Cell Microbiol. 13:1376.
  3. Lepanen, V.M. et al. (2010) Proc. Natl. Acad. Sci. USA 107:2425.
  4. Cai, M. et al. (2017) Vascul. Pharmacol. 88:11.
  5. Nilsson, I. et al. (2010) EMBO J. 29:1377.
  6. Dixelius, J. et al. (2003) J. Biol. Chem. 278:40973.
  7. Albuquerque, R.J. et al. (2009) Nat. Med. 15:1023.
  8. Jin, P. et al. (2008) Arthritis Res. Ther. 10:R73.
  9. Shibuya, M. (2015) Endocr Metab Immune Disord Drug Targets. 15:135.
  10. Farzaneh Behelgardi, M. et al. (2020), Mol Biol Rep. 47:2061.
  11. Lian, L. et al. (2019) BMC Cancer. 19:183.
  12. Hu, C. et al. (2019) Onco. Targets Ther. 12:933.
  13. Gao, F. et al. (2020) Curr. Cancer Drug Targets. 20:3.

Long Name

Vascular Endothelial Growth Factor Receptor 2

Alternate Names

CD309, Flk-1, Flk1, KDR, KRD1, Ly73, VEGF R2

Entrez Gene IDs

3791 (Human); 16542 (Mouse)

Gene Symbol

KDR

UniProt

AAC16450.1

Additional VEGFR2/KDR/Flk-1 Products

Product Documents for Recombinant Human VEGFR2/KDR/Flk-1 Fc Avi-tag Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Human VEGFR2/KDR/Flk-1 Fc Avi-tag Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.